| Name | Title | Contact Details |
|---|
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
nu ear electronics is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioQ Pharma is a late stage specialty pharmaceutical company focused on developing and commercializing a portfolio of large volume ready-to-use infusible pharmaceuticals. Our vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via our proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. Our infusion platform is intended to address some of the most pressing unmet needs in infusion today: cost, medication error, sterility, efficiency, and patient quality of life.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.
JeNu Biosciences was founded by a leading Washington bio scientist and a medical technology entrepreneur. While working on an ultrasound device for topical drug delivery, they became curious about using ultrasound to improve cosmetic skin care product delivery. High energy ultrasound has been proven effective at pushing drugs through the skin, but in the process cells are damaged and high heat causes intense pain. But since cosmetics only need to be absorbed into the top layer of skin rather than through the skin like drugs they thought a low energy ultrasound device might work. After many attempts they proved that low energy ultrasound wouldn`t help on its own. At the same moment, they had the idea that lead to the JeNu System. Rather than using ultrasound energy to vibrate cells in the skin to open up pathways, what if they vibrated microspheres on the skin to open the pathways. This idea lead to patent application 20120271222 and JeNu Biosciences. Launched in 2009, JeNu spent close to $10MM and 5 years on research, development and engineering. JeNu Biosciences is now proud to present the JeNu System. It`s the first pain free, at home, quick way to increase absorption of your favorite skin care products. In just one minute per target area per day the JeNu system is clinically proven to increase absorption by up to 12 times, and improve the efficacy of skin care products by up to 40% in just 7 days.